Lobular Neoplasia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LBL001 MIFTS: 52	Lobular Neoplasia Categories: Cancer diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Lobular Neoplasia

MalaCards integrated aliases for Lobular Neoplasia:

Name: Lobular Neoplasia ¹¹ ¹⁴ ⁷¹ ⁷⁵

Lobular Carcinoma in Situ of Breast ⁷¹ ³³

Lobular Carcinoma in Situ ¹¹ ³¹

Noninfiltrating Lobular Carcinoma Unspecified Site ³³

Noninfiltrating Lobular Carcinoma of Breast ³³

Lobular Carcinoma in Situ Unspecified Site ³³

Non-Infiltrating Lobular Carcinoma ⁷¹

Lobular Intraepithelial Neoplasia ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

In situ neoplasms

Carcinoma in situ of breast

Lobular carcinoma in situ

ICD11: ³³

Neoplasms

In situ neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues

Carcinoma in situ of breast

Lobular carcinoma in situ of breast

External Ids:

Disease Ontology ¹¹ DOID:3010

NCIt ⁴⁹ C27939

ICD10 ³¹ D05.0

ICD11 ³³ 1313183227

UMLS ⁷¹ C0279563 C0334381 C0861352

Sources

Summaries for Lobular Neoplasia

Disease Ontology: ¹¹ A breast carcinoma in situ that is characterized by abnormal cells are found in the lobules (glands that make milk) of the breast.

MalaCards based summary: Lobular Neoplasia, also known as lobular carcinoma in situ of breast, is related to mammary paget's disease and breast duct papilloma. An important gene associated with Lobular Neoplasia is MIR520G (MicroRNA 520g), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Tamoxifen and Afimoxifene have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and smooth muscle, and related phenotypes are Increased cell migration and Increased cell death in HCT116 cells

Wikipedia: ⁷⁵ Lobular neoplasia can refer... more...

Sources

Related Diseases for Lobular Neoplasia

Diseases related to Lobular Neoplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 412)

#	Related Disease	Score	Top Affiliating Genes
1	mammary paget's disease	30.5	PIP PGR ESR1 ERBB2
2	breast duct papilloma	30.3	PTEN PGR
3	microglandular adenosis	30.3	PIP PGR ESR1 ERBB2
4	intraductal papilloma	30.1	PGR KRT5 ESR1 ERBB2
5	comedo carcinoma	30.1	TP53 PGR KRT5 ESR1 ERBB2 BRCA2
6	gynecomastia	30.1	PGR ESR1 ERBB2 CYP19A1
7	benign breast phyllodes tumor	30.0	PGR ESR1
8	breast malignant phyllodes tumor	29.8	TP53 PGR KRT5 ESR1 ERBB2 EGFR
9	tubular adenocarcinoma	29.8	PGR ESR1 ERBB2 CTNNA1 CDH1
10	teratoma	29.8	TP53 PTEN ESR1 ERBB2 CDH1
11	breast disease	29.5	TP53 PGR ESR1 ERBB2 CYP19A1 BRCA2
12	papilloma	29.4	TP53 PTEN KRT5 ERBB2 EGFR CDH1
13	small cell carcinoma	29.3	TP53 PTEN KRT5 EGFR
14	breast fibroadenoma	29.1	TP53 PGR KRT5 ESR1 ERBB2 EGFR
15	adenoid cystic carcinoma	28.9	TP53 PTEN PIK3CA PGR ERBB2 EGFR
16	rhabdomyosarcoma	28.8	TP53 PTEN PIK3CA ESR1 ERBB2 EGFR
17	bilateral breast cancer	28.8	TP53 PTEN PGR PALB2 ESR1 ERBB2
18	ductal carcinoma in situ	28.6	TP53 PTEN PIP PIK3CA PGR KRT5
19	mixed cell type cancer	28.5	TP53 PTEN PIK3CA PGR KRT5 ESR1
20	inherited cancer-predisposing syndrome	28.4	TP53 PTEN PALB2 EGFR CTNNA1 CDH1
21	bap1 tumor predisposition syndrome	28.4	TP53 PTEN PALB2 EGFR CTNNA1 CDH1
22	diffuse gastric cancer	28.3	TP53 PTEN PIK3CA PALB2 ERBB2 CTNND1
23	diffuse gastric and lobular breast cancer syndrome	28.3	TP53 PTEN PIK3CA PALB2 ERBB2 CTNND1
24	hypertrophy of breast	28.2	TP53 PTEN PIK3CA PGR KRT5 ESR1
25	esophageal cancer	28.2	TP53 PTEN PIK3CA ESR1 ERBB2 EGFR
26	breast ductal carcinoma	27.9	TP53 PTEN PIP PGR KRT5 ESR1
27	breast lobular carcinoma	27.8	TP53 PTEN PIP PIK3CA PGR PALB2
28	breast carcinoma in situ	27.7	TP53 PTEN PIP PIK3CA PGR MIR520G
29	lynch syndrome	27.6	TP53 PTEN PIK3CA PGR PALB2 ESR1
30	breast cancer	27.2	TP53 PTEN PIP PIK3CA PGR PALB2
31	uterine corpus adenosarcoma	10.4	PGR ESR1
32	adult cystic nephroma	10.4	PGR ESR1
33	vagina leiomyosarcoma	10.4	PGR ESR1
34	vulvar benign neoplasm	10.4	PGR ESR1
35	her2-receptor negative breast cancer	10.4	PGR ERBB2
36	progesterone resistance	10.4	PGR ESR1
37	hereditary site-specific ovarian cancer syndrome	10.4	BRCA2 BRCA1
38	ovary transitional cell carcinoma	10.4	BRCA2 BRCA1
39	cancerophobia	10.3	BRCA2 BRCA1
40	euryblepharon	10.3	CTNND1 CDH1
41	nosophobia	10.3	BRCA2 BRCA1
42	nipple carcinoma	10.3	PGR ESR1 ERBB2
43	breast mucinous cystadenocarcinoma	10.3	PGR ESR1 ERBB2
44	breast fibroadenosis	10.3	PGR ESR1 ERBB2
45	bulbospinal polio	10.3	PGR ESR1 ERBB2
46	spinal polio	10.3	PGR ESR1 ERBB2
47	glycogen-rich clear cell breast carcinoma	10.3	PGR ESR1 ERBB2
48	breast cystic hypersecretory carcinoma	10.3	PGR ESR1 ERBB2
49	breast-ovarian cancer, familial 2	10.3	BRCA2 BRCA1
50	intravenous leiomyomatosis	10.3	PGR ESR1

Graphical network of the top 20 diseases related to Lobular Neoplasia:

Sources

Symptoms & Phenotypes for Lobular Neoplasia

GenomeRNAi Phenotypes related to Lobular Neoplasia according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased cell migration	GR00055-A-1	9.76	CTNNA1 CTNND1
2	Increased cell migration	GR00055-A-3	9.76	CTNNA1 CTNND1
3	Increased cell death in HCT116 cells	GR00103-A-0	8.96	CASK PIK3CA
4	Decreased viability in pancreas lineage	GR00235-A	8.62	PGR TP53

MGI Mouse Phenotypes related to Lobular Neoplasia:

⁴⁵ (show all 22)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	growth/size/body region	MP:0005378	10.43	BRCA1 BRCA2 CASK CD2BP2 CDH1 CTNNA1
2	neoplasm	MP:0002006	10.41	BRCA1 BRCA2 CDH1 CTNNA1 CTNND1 EGFR
3	nervous system	MP:0003631	10.4	BRCA1 BRCA2 CASK CTNNA1 CTNND1 CYP19A1
4	homeostasis/metabolism	MP:0005376	10.38	BRCA1 BRCA2 CD2BP2 CDH1 CT45A10 CYP19A1
5	endocrine/exocrine gland	MP:0005379	10.36	BRCA1 BRCA2 CDH1 CTNNA1 CTNND1 CYP19A1
6	cellular	MP:0005384	10.36	BRCA1 BRCA2 CASK CD2BP2 CDH1 CTNNA1
7	limbs/digits/tail	MP:0005371	10.34	BRCA1 BRCA2 CASK CTNNA1 EGFR ERBB2
8	digestive/alimentary	MP:0005381	10.32	BRCA1 BRCA2 CASK CDH1 CTNND1 CYP19A1
9	embryo	MP:0005380	10.31	BRCA1 BRCA2 CD2BP2 CDH1 CTNNA1 EGFR
10	normal	MP:0002873	10.29	BRCA1 BRCA2 CDH1 CYP19A1 EGFR ERBB2
11	muscle	MP:0005369	10.27	BRCA1 CTNNA1 CYP19A1 EGFR ERBB2 ESR1
12	cardiovascular system	MP:0005385	10.25	BRCA1 CD2BP2 CDH1 CTNNA1 CYP19A1 EGFR
13	renal/urinary system	MP:0005367	10.18	BRCA1 CD2BP2 CTNND1 CYP19A1 EGFR ESR1
14	immune system	MP:0005387	10.18	BRCA1 BRCA2 CD2BP2 CDH1 CYP19A1 EGFR
15	adipose tissue	MP:0005375	10.09	BRCA1 CYP19A1 EGFR ESR1 PIK3CA PTEN
16	pigmentation	MP:0001186	10.08	BRCA1 CTNNA1 CYP19A1 EGFR PTEN TP53
17	reproductive system	MP:0005389	10.07	BRCA1 BRCA2 CASK CDH1 CYP19A1 EGFR
18	craniofacial	MP:0005382	10	CASK CTNNA1 CTNND1 EGFR ERBB2 KRT5
19	skeleton	MP:0005390	9.93	BRCA1 BRCA2 CASK CTNNA1 CYP19A1 EGFR
20	respiratory system	MP:0005388	9.92	BRCA1 CASK CTNND1 EGFR ERBB2 ESR1
21	mortality/aging	MP:0010768	9.86	BRCA1 BRCA2 CASK CD2BP2 CDH1 CTNNA1
22	integument	MP:0010771	9.53	BRCA1 BRCA2 CASK CDH1 CTNNA1 CTNND1

Sources

Drugs & Therapeutics for Lobular Neoplasia

Drugs for Lobular Neoplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Tamoxifen

Approved

Phase 2, Phase 3

10540-29-1, 54965-24-1

2733526

Afimoxifene

Investigational

Phase 2, Phase 3

68392-35-8

63062

Antineoplastic Agents, Hormonal

Phase 2, Phase 3

Estrogens

Phase 2, Phase 3

Estrogen Receptor Modulators

Phase 2, Phase 3

Estrogen Receptor Antagonists

Phase 2, Phase 3

Estrogen Antagonists

Phase 2, Phase 3

Hormones

Phase 2, Phase 3

Hormone Antagonists

Phase 2, Phase 3

Selective Estrogen Receptor Modulators

Phase 2, Phase 3

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Epirubicin

Approved

Phase 2

56420-45-2

41867

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Vinorelbine

Approved, Investigational

Phase 2

71486-22-1

44424639 60780

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Trastuzumab

Approved, Investigational

Phase 2

180288-69-1

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Ethanol

Approved

Phase 2

64-17-5

702

Naltrexone

Approved, Investigational, Vet_approved

Phase 2

16590-41-3

5360515

Anti-Bacterial Agents

Phase 2

Alkylating Agents

Phase 2

Antirheumatic Agents

Phase 2

Antineoplastic Agents, Alkylating

Phase 2

Antimitotic Agents

Phase 2

Angiogenesis Inhibitors

Phase 2

Antimetabolites

Phase 2

Tubulin Modulators

Phase 2

Antibiotics, Antitubercular

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Immunosuppressive Agents

Phase 2

Immunologic Factors

Phase 2

Narcotic Antagonists

Phase 2

Narcotics

Phase 2

Pasireotide

Approved

Phase 1

396091-73-9

56841596 9941444

Bexarotene

Approved, Investigational

Phase 1

153559-49-0

82146

Zinc cation

Approved, Experimental, Investigational

7440-66-6, 23713-49-7

32051

Iodine

Approved, Investigational

7553-56-2

807

Interventional clinical trials:

(show all 20)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ	Suspended	NCT04570956	Phase 2, Phase 3	Tamoxifen;Topical 4-OHT( 4-hydroxytamoxifen)gel 2 mg/each breast/day;Placebo
2	"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"	Unknown status	NCT01641406	Phase 2	Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
3	Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*)	Recruiting	NCT03979508	Phase 2	Abemaciclib
4	TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions	Recruiting	NCT02928978	Phase 2	Ruxolitinib;Placebo (for Ruxolitinib)
5	A Phase II Study of Accelerated 3 Fraction Photon and Proton Partial Breast External Beam Radiotherapy and Partial Breast Brachytherapy for Early Invasive and Noninvasive Breast Cancer	Active, not recruiting	NCT03391388	Phase 2
6	Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer	Terminated	NCT02137252	Phase 2	Naltrexone;Sugar Pill
7	Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial	Completed	NCT01372644	Phase 1	SOM 230 / Pasireotide
8	Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery	Active, not recruiting	NCT03317405	Phase 1	Endoxifen Hydrochloride
9	A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer	Active, not recruiting	NCT03323658	Phase 1	Bexarotene
10	GLACIER: A Study to Investigate the Genetics of LobulAr Carcinoma In Situ in EuRope	Unknown status	NCT00536718
11	The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma, DCIS, or Atypical Ductal Hyperplasia (ADH) in Patients Diagnosed With Lobular Neoplasia of the Breast by Core Needle Biopsy	Completed	NCT00146536
12	Management of Ductal Carcinoma in Situ (DCIS) or Pure Micro-invasive (DCIS-MI) Extended Breast, Axillary Node Sentinel Site (GAS) When the Diagnosis is Made by Biopsy and Treatment by Mastectomy Immediately. Descriptive Study	Completed	NCT01841749
13	Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ	Completed	NCT00620087
14	Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ	Completed	NCT00581750
15	Cool Down With EMBr: Enhancing Menopausal Hot Flash Symptom Reduction After Breast Cancer	Recruiting	NCT05086705
16	Improving Well-Being for Individuals With Persistent Pain After Surgery for Breast Cancer, Lobular Carcinoma in Situ, or Ductal Carcinoma in Situ: A Randomized Clinical Trial That Compares Three Behavioral Intervention Strategies and Examines Psychological Factors as Drivers of the Continuing Burden of Persistent Pain	Recruiting	NCT04225585
17	Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into Care (MiChoice)	Recruiting	NCT04496739
18	Energy Balance and Breast Cancer Aspects-II Study	Active, not recruiting	NCT02240836
19	Efficacy, Safety, Cosmesis and Patient Satisfaction With Vacuum-Assisted Percutaneous Excision (VAPE) Compared With Standard Surgical Excision (X) of Non-malignant, Borderline or High-risk Breast Lesions: A Randomized Controlled Trial	Not yet recruiting	NCT03868475
20	Longitudinal Study Evaluating the Impact of Dietary Inflammatory Potential on Breast Cancer Risk in a Cohort of Women Followed in the Breast Cancer Prevention Clinic at the Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute	Not yet recruiting	NCT05178498

Search NIH Clinical Center for Lobular Neoplasia

Sources

Genetic Tests for Lobular Neoplasia

Sources

Anatomical Context for Lobular Neoplasia

Organs/tissues related to Lobular Neoplasia:

MalaCards : Breast, Lymph Node, Smooth Muscle, Testis, Prostate, Colon, Lung

Sources

Publications for Lobular Neoplasia

Articles related to Lobular Neoplasia:

(show top 50) (show all 1241)

#	Title	Authors	PMID	Year
1	Lobular Neoplasia. ⁶²	Lunt L...Perez CB	36335930	2022
2	High-risk and selected benign breast lesions diagnosed on core needle biopsy: Evidence for and against immediate surgical excision. ⁶²	Harbhajanka A...Calhoun BC	35654997	2022
3	Improving well-being for individuals with persistent pain after surgery for breast cancer, lobular carcinoma in situ, or ductal carcinoma in situ: A randomized clinical trial. ⁶²	Stalls JM...Shelby RA	36152791	2022
4	Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS. ⁶²	Nakhlis F...King TA	35771367	2022
5	Lobular Carcinoma In Situ during Preoperative Biopsy and the Rate of Upgrade. ⁶²	Lee J...Park BW	34942684	2022
6	The Influence of Body Mass Index on the Histopathology and Outcomes of Patients Diagnosed with Atypical Breast Lesions. ⁶²	Miller KN...Plichta JK	35951136	2022
7	Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: recommendations from the International Collaboration on Cancer Reporting (ICCR). ⁶²	Fox SB...Tan PH	35869801	2022
8	ASO Author Reflections: Is Surgical Excision Necessary in Lobular Neoplasia with Synchronous Breast Carcinoma? ⁶²	Crary IL...Flanagan MR	35818020	2022
9	ASO Visual Abstract: Risk of Lobular Neoplasia Upgrade with Synchronous Carcinoma. ⁶²	Crary IL...Flanagan MR	35857198	2022
10	Risk of Lobular Neoplasia Upgrade with Synchronous Carcinoma. ⁶²	Crary IL...Flanagan MR	35802213	2022
11	Value of Long-term Follow-up in Surgically Excised Lesions of Uncertain Malignant Potential in the Breast - Is 5 Years Necessary? ⁶²	Hennessy G...Hill AD	35732544	2022
12	Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity. ⁶²	Soong TR...Harrison BT	35477749	2022
13	Management of breast complaints and high-risk lesions. ⁶²	Pleasant V	35570155	2022
14	Screening MRI Does Not Increase Cancer Detection or Result in an Earlier Stage at Diagnosis for Patients with High-Risk Breast Lesions: A Propensity Score Analysis. ⁶²	Laws A...King TA	36171529	2022
15	Fine-needle aspiration of intramammary lymph nodes: a clinical, radiographic, and cytologic review. ⁶²	Cheng L...Gattuso P	36270911	2022
16	Accuracy of the Breast Cancer Surveillance Consortium Model Among Women with LCIS. ⁶²	Eroglu I...Pilewskie ML	35595928	2022
17	Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses. ⁶²	Zhang Y...Zhang Z	35666367	2022
18	The positive predictive value of vacuum assisted biopsy (VAB) in predicting final histological diagnosis for breast lesions of uncertain malignancy (B3 lesions): A systematic review & meta-analysis. ⁶²	Cullinane C...Paul Redmond H	35491362	2022
19	Upgrade Rates of Pure, Radiology-Pathology Concordant Lobular Neoplasia Diagnosed on Breast Core Needle Biopsy: Is Surgical Excision Warranted? ⁶²	Karimi Z...Mehta TS	34702673	2022
20	Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ. ⁶²	Mallory MA...Pilewskie ML	35488092	2022
21	Metaplastic Matrix-Producing Carcinoma and Apocrine Lobular Carcinoma In Situ Associated with Microglandular Adenosis: A Unique Case Report. ⁶²	Koufopoulos N...Khaldi L	35741268	2022
22	Strategies to Identify and Recruit Women at High Risk for Breast Cancer to a Randomized Controlled Trial of Web-based Decision Support Tools. ⁶²	McGuinness JE...Crew KD	35412592	2022
23	Lobular Carcinoma In Situ Incidentally Detected by Dual-Energy Computed Tomography ⁶²	Erdemir AG...Akpinar E	35466660	2022
24	Screening MRI in Women at Intermediate Breast Cancer Risk: An Update of the Recent Literature. ⁶²	Bahl M	35783682	2022
25	The morphologic spectrum of lobular carcinoma in situ (LCIS) observations on clinical significance, management implications and diagnostic pitfalls of classic, florid and pleomorphic LCIS. ⁶²	Brogi E	35567633	2022
26	Effective Surveillance of High-Risk Women. ⁶²	Lotz M...Pories SE	34429241	2022
27	Additional Excision Biopsy in Patients With Atypical Ductal Hyperplasia at Ultrasound-guided Vacuum-assisted Breast Biopsy. ⁶²	Park HL...Kim JH	35347040	2022
28	Factors Indicating Surgical Excision in Classical Type of Lobular Neoplasia of the Breast. ⁶²	Elfgen C...Varga Z	35702498	2022
29	Malignancy Rate and Malignancy Risk Assessment in Different Lesions of Uncertain Malignant Potential in the Breast (B3 Lesions): An Analysis of 192 Cases from a Single Institution. ⁶²	Mohrmann S...Roth KS	35702494	2022
30	Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. ⁶²	Laws A...King TA	34554341	2022
31	Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation. ⁶²	Matar R...Pilewskie M	34671879	2022
32	[Variants of breast lobular neoplasia: differential diagnosis and new molecular insight]. ⁶²	Zhang Z...Tang P	35152642	2022
33	Evidence-Based Pragmatic Approach to the Management of Borderline or High-Risk Breast Lesions. ⁶²	Lamb LR...Bahl M	34286593	2022
34	Prognostic Significance of Lobular Carcinoma In-Situ (LCIS) Diagnosed Alongside Invasive Breast Cancer. ⁶²	Braasch MC...Larson KE	35283633	2022
35	Multimodal Imaging of Target Detection Algorithm under Artificial Intelligence in the Diagnosis of Early Breast Cancer. ⁶²	Jiang M...Luo Y	35047160	2022
36	Risk management recommendations and patient acceptance vary with high-risk breast lesions. ⁶²	Beck AC...Lizarraga IM	34325908	2022
37	Papillary lesions of the breast. ⁶²	Kulka J...Lax SF	34734332	2022
38	Apocrine lesions of the breast. ⁶²	Quinn CM...Wells C	34537861	2022
39	Early onset, delayed diagnosis and laterality of breast carcinoma: Evidence from a tertiary care hospital. ⁶²	Sume BW...Merkeb Alamneh Y	35910817	2022
40	Histiocytoid variant of invasive lobular breast carcinoma. A case report and literature review. ⁶²	Aldulaijan FA...Alwabari A	34868577	2021
41	Co-expression of transcription factor AP-2beta (TFAP2B) and GATA3 in human mammary epithelial cells with intense, apicobasal immunoreactivity for CK8/18. ⁶²	Raap M...Christgen M	34117603	2021
42	Is there an increasing trend of risk-reducing prophylactic mastectomy procedure in preventing breast cancer among women? ⁶²	Arslan B...Ozdemir AA	35677477	2021
43	[Updated WHO classification of tumors of the breast]. ⁶²	Lebeau A	34751805	2021
44	Lobular neoplasia detected at MRI-guided biopsy: imaging findings and outcomes. ⁶²	Chikarmane SA...Gombos EC	33838434	2021
45	Trends in incidence, treatment, survival and subsequent breast cancer in lobular carcinoma in situ in the Netherlands: A population-based analysis. ⁶²	van Maaren MC...Siesling S	34428722	2021
46	Photodynamic Therapy Induced Cell Death Mechanisms in Breast Cancer. ⁶²	Mokoena DR...Abrahamse H	34638847	2021
47	Role of breast MRI in predicting histologic upgrade risks in high-risk breast lesions: A review. ⁶²	Li X...Yan F	34303150	2021
48	Comparison of the Imaging Features of Lobular Carcinoma In Situ and Invasive Lobular Carcinoma of the Breast. ⁶²	Yoon GY...Gong G	36238391	2021
49	Impact of lobular carcinoma in situ on local recurrence in breast cancer treated with breast conservation therapy: a systematic review and meta-analysis. ⁶²	Harris CG...Eslick GD	33634956	2021
50	Kuwait National Mammography Screening Program: outcomes of 5 years of screening in Kuwaiti women. ⁶²	Alkhawari HA...AlKandari LA	34618610	2021

Sources

Genes for Lobular Neoplasia

Genes related to Lobular Neoplasia (0 elite genes):

(show all 21)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MIR520G	MicroRNA 520g	RNA Gene	8.28	DISEASES inferred ¹⁴ ¹⁴
2	ESR1	Estrogen Receptor 1	Protein Coding	7.54	DISEASES inferred ¹⁴
3	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	7.52	DISEASES inferred ¹⁴
4	PGR	Progesterone Receptor	Protein Coding	7.5	DISEASES inferred ¹⁴
5	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	7.34	DISEASES inferred ¹⁴
6	CDH1	Cadherin 1	Protein Coding	7.28	DISEASES inferred ¹⁴
7	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	7.14	DISEASES inferred ¹⁴
8	CD2BP2	CD2 Cytoplasmic Tail Binding Protein 2	Protein Coding	6.91	DISEASES inferred ¹⁴
9	CASK	Calcium/Calmodulin Dependent Serine Protein Kinase	Protein Coding	6.63	DISEASES inferred ¹⁴
10	CT45A10	Cancer/Testis Antigen Family 45 Member A10	Protein Coding	6.46	DISEASES inferred ¹⁴ ¹⁴
11	CTNND1	Catenin Delta 1	Protein Coding	6.4	DISEASES inferred ¹⁴
12	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	6.24	DISEASES inferred ¹⁴
13	KRT5	Keratin 5	Protein Coding	6.06	DISEASES inferred ¹⁴
14	PIP	Prolactin Induced Protein	Protein Coding	5.99	DISEASES inferred ¹⁴
15	TP53	Tumor Protein P53	Protein Coding	5.94	DISEASES inferred ¹⁴
16	PALB2	Partner And Localizer Of BRCA2	Protein Coding	5.45	DISEASES inferred ¹⁴
17	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	5.4	DISEASES inferred ¹⁴
18	EGFR	Epidermal Growth Factor Receptor	Protein Coding	5.33	DISEASES inferred ¹⁴
19	PTEN	Phosphatase And Tensin Homolog	Protein Coding	5.22	DISEASES inferred ¹⁴
20	CTNNA1	Catenin Alpha 1	Protein Coding	5.19	DISEASES inferred ¹⁴
21	CTNNB1	Catenin Beta 1	Protein Coding	5.19	DISEASES inferred ¹⁴

Sources

Variations for Lobular Neoplasia

Cosmic variations for Lobular Neoplasia:

⁸ (show top 50) (show all 75)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM87752998	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.1676G>A	p.S559N	16:68819390-68819390	10
2	COSM107640435	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.893C>A	p.A298D	16:68811744-68811744	10
3	COSM145160856	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.770A>G	p.D257G	16:68810279-68810279	10
4	COSM142974226	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.763C>T	p.Q255*	16:68810272-68810272	10
5	COSM144547163	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.734C>T	p.P245L	16:68810243-68810243	10
6	COSM145165659	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.1866-4524G>A	p.?	16:68829679-68829679	10
7	COSM144546942	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.274C>T	p.H92Y	16:68801780-68801780	10
8	COSM107640594	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.2138G>A	p.R713K	16:68829679-68829679	10
9	COSM144547899	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.856G>A	p.A286T	16:68811707-68811707	10
10	COSM144546390	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.1595G>A	p.W532*	16:68819309-68819309	10
11	COSM145153147	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.763C>T	p.Q255*	16:68810272-68810272	10
12	COSM142988181	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.893C>A	p.A298D	16:68811744-68811744	10
13	COSM142988327	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.2384G>A	p.R795K	16:68829679-68829679	10
14	COSM145165703	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.1866-5976C>T	p.?	16:68828227-68828227	10
15	COSM87754517	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.274C>T	p.H92Y	16:68801780-68801780	10
16	COSM107628859	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.763C>T	p.Q255*	16:68810272-68810272	10
17	COSM142988364	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.2281C>T	p.P761S	16:68828227-68828227	10
18	COSM145153098	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.760G>T	p.D254Y	16:68810269-68810269	10
19	COSM145165484	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.856G>A	p.A286T	16:68811707-68811707	10
20	COSM144547285	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.1854-789C>T	p.?	16:68833402-68833402	10
21	COSM87755934	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.893C>A	p.A298D	16:68811744-68811744	10
22	COSM144548109	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.1853+1673C>T	p.?	16:68828227-68828227	10
23	COSM142986905	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.922G>A	p.D308N	16:68811773-68811773	10
24	COSM144545407	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.1676G>A	p.S559N	16:68819390-68819390	10
25	COSM142986026	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.1739G>A	p.S580N	16:68819390-68819390	10
26	COSM145164442	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.274C>T	p.H92Y	16:68801780-68801780	10
27	COSM144531682	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.763C>T	p.Q255*	16:68810272-68810272	10
28	COSM144541605	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.770A>G	p.D257G	16:68810279-68810279	10
29	COSM142983154	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.770A>G	p.D257G	16:68810279-68810279	10
30	COSM87740032	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.760G>T	p.D254Y	16:68810269-68810269	10
31	COSM87754742	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.734C>T	p.P245L	16:68810243-68810243	10
32	COSM107640429	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.856G>A	p.A286T	16:68811707-68811707	10
33	COSM144548251	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.1830+1468G>A	p.?	16:68823587-68823587	10
34	COSM107639825	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.2369C>T	p.S790L	16:68833402-68833402	10
35	COSM87754074	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.1595G>A	p.W532*	16:68819309-68819309	10
36	COSM142988178	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.856G>A	p.A286T	16:68811707-68811707	10
37	COSM87754888	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.2552C>T	p.S851L	16:68833402-68833402	10
38	COSM144531632	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.760G>T	p.D254Y	16:68810269-68810269	10
39	COSM144546606	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.922G>A	p.D308N	16:68811773-68811773	10
40	COSM107639170	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.922G>A	p.D308N	16:68811773-68811773	10
41	COSM145165488	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.893C>A	p.A298D	16:68811744-68811744	10
42	COSM107640262	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.1183G>A	p.V395M	16:68815560-68815560	10
43	COSM87756131	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.2321G>A	p.R774K	16:68829679-68829679	10
44	COSM87749984	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.770A>G	p.D257G	16:68810279-68810279	10
45	COSM142974180	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.760G>T	p.D254Y	16:68810269-68810269	10
46	COSM107638085	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.1493G>A	p.S498N	16:68819390-68819390	10
47	COSM107640734	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.1942G>A	p.A648T	16:68823587-68823587	10
48	COSM107639473	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.274C>T	p.H92Y	16:68801780-68801780	10
49	COSM144547907	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.893C>A	p.A298D	16:68811744-68811744	10
50	COSM142988493	CDH1	breast,NS,carcinoma in situ,lobular carcinoma in situ	c.2188G>A	p.A730T	16:68823587-68823587	10

Sources

Expression for Lobular Neoplasia

Search GEO for disease gene expression data for Lobular Neoplasia.

Sources

Pathways for Lobular Neoplasia

Pathways related to Lobular Neoplasia according to GeneCards Suite gene sharing:

(show top 50) (show all 55)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.8	TP53 PTEN PIP ESR1 ERBB2 EGFR
2	Signal Transduction ⁶⁶	13.76	TP53 PTEN PIK3CA PGR ESR1 ERBB2
3	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.75	TP53 PTEN PIK3CA PALB2 ESR1 ERBB2
4	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.29	PTEN PIP ERBB2 EGFR CTNND1 CTNNA1
5	PIP3 activates AKT signaling ⁶⁶ Show member pathways Intracellular signaling by second messengers ⁶⁶ PTEN Regulation ⁶⁶ Regulation of PTEN gene transcription ⁶⁶ Regulation of PTEN localization ⁶⁶	13.06	TP53 PTEN PIK3CA ESR1 ERBB2 EGFR
6	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.83	CTNNA1 CTNND1 EGFR ERBB2 ESR1 PGR
7	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ⁶⁶ Show member pathways Constitutive Signaling by Aberrant PI3K in Cancer ⁶⁶ Negative regulation of the PI3K/AKT network ⁶⁶ PI3K/AKT Signaling in Cancer ⁶⁶	12.68	EGFR ERBB2 ESR1 PIK3CA PTEN
8	Cell junction organization ⁶⁶ Show member pathways Adherens junctions interactions ⁶⁶ Cell-Cell communication ⁶⁶ Cell-cell junction organization ⁶⁶ Cell-extracellular matrix interactions ⁶⁶ Localization of the PINCH-ILK-PARVIN complex to focal adhesions ⁶⁶ Nectin/Necl trans heterodimerization ⁶⁶ Regulation of cytoskeletal remodeling and cell spreading by IPP complex components ⁶⁶ SDK interactions ⁶⁶ Signal regulatory protein family interactions ⁶⁶ Tight junction interactions ⁶⁶ Type I hemidesmosome assembly ⁶⁶	12.68	PIK3CA KRT5 CTNND1 CTNNA1 CDH1 CASK
9	Malignant pleural mesothelioma ⁷⁴	12.59	TP53 PTEN PIK3CA EGFR CTNNA1 CDH1
10	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.49	TP53 PIK3CA ERBB2 EGFR CDH1
11	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.48	TP53 PTEN PIK3CA ERBB2 EGFR CTNNA1
12	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.43	TP53 PIK3CA ERBB2 EGFR
13	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.43	TP53 PTEN PIK3CA ESR1 ERBB2 CDH1
14	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.38	PIK3CA ERBB2 EGFR CTNNA1 CDH1
15	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.32	PIK3CA ESR1 ERBB2 EGFR
16	Focal adhesion ⁷⁴	12.28	PTEN PIK3CA ERBB2 EGFR
17	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.21	TP53 PTEN PIK3CA ERBB2 EGFR
18	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.13	PTEN PIK3CA ERBB2 EGFR
19	mTOR Signaling ⁶⁵	12.09	EGFR ERBB2 PTEN TP53
20	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.07	PIK3CA PGR ESR1 ERBB2 EGFR
21	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.04	TP53 PTEN PIK3CA PGR ESR1 ERBB2
22	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	12.03	TP53 PIK3CA ERBB2 EGFR
23	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	11.97	PTEN PIK3CA ERBB2 EGFR
24	DNA damage response (only ATM dependent) ⁷⁴	11.92	TP53 PTEN PIK3CA ERBB2
25	DNA IR-double strand breaks and cellular response via ATM ⁷⁴ Show member pathways ATM pathway ⁶¹ DNA damage_DNA-damage-induced responses ²²	11.89	TP53 BRCA2 BRCA1
26	Small cell lung cancer ⁷⁴	11.87	TP53 PTEN PIK3CA
27	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors ⁶⁶ Show member pathways Activation of the TFAP2 (AP-2) family of transcription factors ⁶⁶ Negative regulation of activity of TFAP2 (AP-2) family transcription factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of cell cycle factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of growth factors and their receptors ⁶⁶ TFAP2 (AP-2) family regulates transcription of other transcription factors ⁶⁶ TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation ⁶⁶	11.84	ESR1 ERBB2 EGFR
28	DNA IR-damage and cellular response via ATR ⁷⁴	11.81	TP53 PALB2 BRCA2 BRCA1
29	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.8	TP53 BRCA2 BRCA1
30	16p11.2 proximal deletion syndrome ⁷⁴	11.75	TP53 PTEN ESR1
31	Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ⁶¹	11.73	PIK3CA CTNNA1 CDH1
32	AP-1 transcription factor network ⁶¹	11.71	TP53 PTEN ESR1
33	Validated nuclear estrogen receptor alpha network ⁶¹	11.68	BRCA1 ESR1 PGR
34	Head and neck squamous cell carcinoma ⁷⁴	11.63	TP53 PTEN PIK3CA ERBB2 EGFR
35	Copper homeostasis ⁷⁴ Show member pathways Copper metabolism ⁷⁴ Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) ⁶⁶	11.62	TP53 PTEN PIK3CA
36	FGF signaling pathway ⁶¹	11.59	PIK3CA CTNND1 CDH1
37	Posttranslational regulation of adherens junction stability and dissassembly ⁶¹	11.54	EGFR CTNND1 CTNNA1 CDH1
38	Arf6 trafficking events ⁶¹	11.52	CTNND1 CTNNA1 CDH1
39	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.51	BRCA1 ERBB2 PIK3CA PTEN TP53
40	Cell adhesion_Cadherin-mediated cell adhesion ²²	11.44	CTNND1 CTNNA1 CDH1
41	Ovarian tumor domain proteases ⁶⁶	11.43	TP53 PTEN ESR1
42	Stabilization and expansion of the E-cadherin adherens junction ⁶¹	11.43	CDH1 CTNNA1 CTNND1 EGFR
43	Integrated cancer pathway ⁷⁴	11.41	TP53 PTEN BRCA1
44	Bladder cancer ⁷⁴	11.4	TP53 ERBB2 EGFR CDH1
45	Integrated breast cancer pathway ⁷⁴	11.4	TP53 PTEN ESR1 EGFR CYP19A1 CDH1
46	E-cadherin signaling in the nascent adherens junction ⁶¹ Show member pathways AlphaE beta7 integrin cell surface interactions ⁶¹	11.36	PIK3CA CTNND1 CTNNA1 CDH1
47	a6b1 and a6b4 Integrin signaling ⁶¹	11.33	PIK3CA ERBB2 EGFR CDH1
48	N-cadherin signaling events ⁶¹	11.29	PIK3CA CTNND1 CTNNA1
49	Nectin adhesion pathway ⁶¹	11.24	CDH1 CTNNA1 PIK3CA
50	Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) ⁷⁴	11.21	PGR ESR1 ERBB2 EGFR

Sources

GO Terms for Lobular Neoplasia

Cellular components related to Lobular Neoplasia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nuclear ubiquitin ligase complex	GO:0000152	9.46	BRCA2 BRCA1
2	catenin complex	GO:0016342	9.43	CTNND1 CTNNA1 CDH1
3	DNA repair complex	GO:1990391	9.1	PALB2 BRCA2 BRCA1

Biological processes related to Lobular Neoplasia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of apoptotic process	GO:0043066	10.1	TP53 PTEN PALB2 ERBB2 EGFR CTNNA1
2	phosphatidylinositol 3-kinase signaling	GO:0014065	9.8	PTEN PIK3CA ERBB2
3	positive regulation of RNA polymerase II transcription preinitiation complex assembly	GO:0045899	9.46	TP53 ESR1
4	chordate embryonic development	GO:0043009	9.43	BRCA2 BRCA1
5	cellular response to ionizing radiation	GO:0071479	9.43	TP53 BRCA2 BRCA1
6	positive regulation of miRNA maturation	GO:1903800	9.37	TP53 EGFR
7	cellular response to indole-3-methanol	GO:0071681	9.1	CTNNA1 CDH1 BRCA1

Molecular functions related to Lobular Neoplasia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	enzyme binding	GO:0019899	9.93	TP53 PTEN PGR ESR1 EGFR BRCA1
2	identical protein binding	GO:0042802	9.7	BRCA1 BRCA2 CDH1 CT45A10 CTNNA1 EGFR
3	beta-catenin binding	GO:0008013	9.56	ESR1 CTNND1 CTNNA1 CDH1